Emcure Pharmaceuticals Share Price Jumps Over 5% After Novo Nordisk Partnership to Commercialize Poviztra in India

Mumbai, November 10, 2025:  The share price of Emcure Pharmaceuticals Limited (NSE: EMCURE, BSE: 544210) climbed 4.59% on Monday, following the company’s announcement of a strategic collaboration with Novo Nordisk India to distribute and commercialize Poviztra®, a semaglutide injection for weight management, across India.

The stock opened and closed at ₹1,362.40, reflecting strong investor interest post-announcement. The partnership positions Emcure to expand its presence in India’s fast-growing anti-obesity and metabolic health segment.

At the close of trade, the company’s market capitalisation stood at ₹25,826.30 crore, while its price-to-earnings (P/E) ratio was 34.70, notably higher than the industry average signalling robust market confidence in its growth outlook.

Emcure Pharmaceuticals Ltd is one of the leading companies in the list of 15 pharmaceutical companies in India, according to their domestic sales revenue, held by Emcure Pharmaceuticals Ltd, founded in 1981 and based in Pune, India. The firm designs, produces, and markets very diverse pharmaceutical products in over 70 nations, both in Europe and Canada. Emcure is listed on the Nifty Smallcap 250 of the NSE and BSE.

Details of the Partnership

As part of this partnership, Emcure Pharma is the first Indian company to have exclusive rights to distribute and commercialize Poviztra® (semaglutide injection 2.4 mg), which is a second brand of Wegovy®. Poviztra is indicated for chronic weight management and decreased cardiovascular risk in adults with obesity or overweight. This expanded access to high-quality, effective treatment to help manage obesity and/or overweight is made possible through Emcure’s strong marketing and distribution capability.

Management Commentary

Satish Mehta, CEO and Managing Director of Emcure Pharma, considers it an achievement and said that there is great excitement to collaborate with Novo Nordisk India to launch Poviztra® in India. He said, “We believe our deep experience in the various segments of India and the marketing capabilities we have developed will help us get this molecule to the patients who need it the most”.

Also, Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk, stated, “We are excited to combine Novo Nordisk’s leadership in GLP-1 therapies with Emcure’s marketing expertise to increase access to treatment for obesity for people in India.”

Both Poviztra and Wegovy are semaglutide-based medicines, which are given once a week with the help of a pen device. The medications have been tested for up to a 20 percent reduction in body weight in eligible patients and have been used in an extensive number of clinical studies in the STEP and SELECT programs.

India is experiencing an increasing obesity problem with 254 million individuals with generalized obesity and 351million individuals with abdominal obesity. The relationship is anticipated to expand the availability of advanced GLP-1-based therapy in one of the largest markets in the world in terms of chronic weight management solutions.

REF: https://nsearchives.nseindia.com/corporate/EMCURE_10112025112052_EPLIntimationPressRelease.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations